RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II

Bone

Volumn 48, Issue 4, 2011, Pages 938-944

  Hemingway, F ^a   Taylor, R ^a   Knowles, H J ^a   Athanasou, N A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

APRIL; IGF; NGF; Osteoclasts; RANKL

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; COLONY STIMULATING FACTOR 1; INTERLEUKIN 6; NERVE GROWTH FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTINUCLEAR CELL; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCLASTOMA; OSTEOLYSIS; STROMA CELL;

B-CELL ACTIVATING FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; NERVE GROWTH FACTOR; OSTEOCLASTS; RANK LIGAND; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 79952699649     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.12.023     Document Type: Article

References (61)

1. Massey H.M., Flanagan A.M. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 1999, 106:167-170.
2. Hattner R., Epker B.N., Frost H.M. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 1965, 206:489-490.
3. Parfitt A.M. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 1982, 4:1-6.
4. Hattersley G., Owens J., Flanagan A.M., Chambers T.J. Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitro. Biochem Biophys Res Commun 1991, 177:526-531.
5. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
6. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
7. Pfeilschifter J., Chenu C., Bird A., Mundy G.R., Roodman G.D. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res 1989, 4:113-118.
8. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-286.
9. Edwards J.R., Sun S.G., Locklin R., Shipman C.M., Adamopoulos I.E., Athanasou N.A., et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum 2006, 54:1451-1462.
10. Ishimi Y., Miyaura C., Jin C.H., Akatsu T., Abe E., Nakamura Y., et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990, 145:3297-3303.
11. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993, 90:11924-11928.
12. Fujikawa Y., Sabokbar A., Neale S.D., Itonaga I., Torisu T., Athanasou N.A. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone 2001, 28:261-267.
13. Itonaga I., Sabokbar A., Sun S.G., Kudo O., Danks L., Ferguson D., et al. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 2004, 34:57-64.
14. Roodman G.D., Kurihara N., Ohsaki Y., Kukita A., Hosking D., Demulder A., et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992, 89:46-52.
15. Mills B.G., Frausto A. Cytokines expressed in multinucleated cells: Paget's disease and giant cell tumors versus normal bone. Calcif Tissue Int 1997, 61:16-21.
16. Walsh N.C., Crotti T.N., Goldring S.R., Gravallese E.M. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005, 208:228-251.
17. Cauley J.A., Danielson M.E., Boudreau R.M., Forrest K.Y., Zmuda J.M., Pahor M., et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res 2007, 22:1088-1095.
18. Hahne M., Kataoka T., Schroter M., Hofmann K., Irmler M., Bodmer J.L., et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998, 188:1185-1190.
19. Kelly K., Manos E., Jensen G., Nadauld L., Jones D.A. APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 2000, 60:1021-1027.
20. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
21. Moreaux J., Cremer F.W., Reme T., Raab M., Mahtouk K., Kaukel P., et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005, 106:1021-1030.
22. Abe M., Kido S., Hiasa M., Nakano A., Oda A., Amou H., et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006, 20:1313-1315.
23. Asaumi K., Nakanishi T., Asahara H., Inoue H., Takigawa M. Expression of neurotrophins and their receptors (TRK) during fracture healing. Bone 2000, 26:625-633.
24. Frenkel S.R., Guerra L.A., Mitchell O.G., Singh I.J. Nerve growth factor in skeletal tissues of the embryonic chick. Cell Tissue Res 1990, 260:507-511.
25. Grills B., Schuijers J. Immunohistochemical localization of nerve growth factor in fractured and unfractured rat bone. Acta Orthop Scand 1998, 69:415-419.
26. Hukkanen M., Konttinen Y., Santavirta S., Paavolainen P., Gu X.-H., Terenghi G., et al. Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neural involvement in bone growth and remodelling. Neuroscience 1993, 54:969-979.
27. Mohan S., Jennings J.C., Linkhart T.A., Baylink D.J. Primary structure of human skeletal growth factor: homology with human insulin-like growth factor-II. Biochim Biophys Acta 1988, 966:44-55.
28. Hayden J.M., Mohan S., Baylink D.J. The insulin-like growth factor system and the coupling of formation to resorption. Bone 1995, 17:93S-98S.
29. Hill P.A., Reynolds J.J., Meikle M.C. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. Endocrinology 1995, 136:124-131.
30. Fukuoka H., Aoyama M., Miyazawa K., Asai K., Goto S. Hypoxic stress enhances osteoclast differentiation via increasing IGF2 production by non-osteoclastic cells. Biochem Biophys Res Commun 2005, 328:885-894.
31. Mochizuki H., Hakeda Y., Wakatsuki N., Usui N., Akashi S., Sato T., et al. Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology 1992, 131:1075-1080.
32. Nakao K., Aoyama M., Fukuoka H., Fujita M., Miyazawa K., Asai K., et al. IGF2 modulates the microenvironment for osteoclastogenesis. Biochem Biophys Res Commun 2009, 378:462-466.
33. Johansson A.G., Lindh E., Ljunghall S. Insulin-like growth factor I stimulates bone turnover in osteoporosis. Lancet 1992, 339:1619.
34. Rosen C.J., Donahue L.R., Hunter S.J. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994, 206:83-102.
35. Middleton J., Arnott N., Walsh S., Beresford J. Osteoblasts and osteoclasts in adult human osteophyte tissue express the mRNAs for insulin-like growth factors I and II and the type 1 IGF receptor. Bone 1995, 16:287-293.
36. Perrini S., Laviola L., Carreira M.C., Cignarelli A., Natalicchio A., Giorgino F. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol 2010, 205:201-210.
37. Lader C.S., Flanagan A.M. Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology 1998, 139:3157-3164.
38. Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000, 275:4858-4864.
39. Kudo O., Fujikawa Y., Itonaga I., Sabokbar A., Torisu T., Athanasou N.A. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J Pathol 2002, 198:220-227.
40. Lau Y.S., Sabokbar A., Gibbons C.L., Giele H., Athanasou N. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005, 36:945-954.
41. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002, 109:59-68.
42. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003, 62:168-171.
43. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005, 1050:34-39.
44. Neri P., Kumar S., Fulciniti M.T., Vallet S., Chhetri S., Mukherjee S., et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007, 13:5903-5909.
45. Mhawech-Fauceglia P., Kaya G., Sauter G., McKee T., Donze O., Schwaller J., et al. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 2006, 80:697-704.
46. Yao Z., Xing L., Boyce B.F. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest 2009, 119:3024-3034.
47. Hohmann E.L., Elde R.P., Rysavy J.A., Einzig S., Gebhard R.L. Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. Science 1986, 232:868-871.
48. Serre C.M., Farlay D., Delmas P.D., Chenu C. Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone 1999, 25:623-629.
49. Wang L., Zhou S., Liu B., Lei D., Zhao Y., Lu C., et al. Locally applied nerve growth factor enhances bone consolidation in a rabbit model of mandibular distraction osteogenesis. J Orthop Res 2006, 24:2238-2245.
50. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech 2002, 58:77-84.
51. Bautista C.M., Mohan S., Baylink D.J. Insulin-like growth factors I and II are present in the skeletal tissues of ten vertebrates. Metabolism 1990, 39:96-100.
52. Zhang M., Xuan S., Bouxsein M.L., von Stechow D., Akeno N., Faugere M.C., et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002, 277:44005-44012.
53. Wang Y., Nishida S., Elalieh H.Z., Long R.K., Halloran B.P., Bikle D.D. Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res 2006, 21:1350-1358.
54. Guicheux J., Heymann D., Rousselle A.V., Gouin F., Pilet P., Yamada S., et al. Growth hormone stimulatory effects on osteoclastic resorption are partly mediated by insulin-like growth factor I: an in vitro study. Bone 1998, 22:25-31.
55. Bautista C.M., Baylink D.J., Mohan S. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone. Biochem Biophys Res Commun 1991, 176:756-763.
56. Piper K., Boyde A., Jones S.J. The relationship between the number of nuclei of an osteoclast and its resorptive capability in vitro. Anat Embryol (Berl) 1992, 186:291-299.
57. Lees R.L., Sabharwal V.K., Heersche J.N. Resorptive state and cell size influence intracellular pH regulation in rabbit osteoclasts cultured on collagen-hydroxyapatite films. Bone 2001, 28:187-194.
58. Yagi M., Miyamoto T., Sawatani Y., Iwamoto K., Hosogane N., Fujita N., et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005, 202:345-351.
59. Anderson P., Kopp L., Anderson N., Cornelius K., Herzog C., Hughes D., et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs 2008, 17:1703-1715.
60. Avnet S., Sciacca L., Salerno M., Gancitano G., Cassarino M.F., Longhi A., et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 2009, 69:2443-2452.
61. Thomas D., Henshaw R., Skubitz K., Chawla S., Staddon A., Blay J.Y., et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280.